POTASSIUM CHLORIDE 10MEQ
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ (POTASSIUM CHLORIDE 10MEQ).
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions.
| Metabolism | Not metabolized; excreted primarily by the kidneys (90%) and to a small extent in feces via intestinal secretion. |
| Excretion | Primarily renal (≥90% of absorbed potassium is excreted via kidneys; small amounts lost in feces and sweat). |
| Half-life | Not applicable as potassium is an electrolyte; its elimination follows first-order kinetics with a terminal half-life of approximately 2–3 hours in healthy individuals, reflecting rapid redistribution and renal clearance. |
| Protein binding | Minimal; approximately 5–10% bound to albumin. |
| Volume of Distribution | 0.5–1.0 L/kg; reflects distribution into total body water (intracellular and extracellular compartments). |
| Bioavailability | Oral: 90–100% (well absorbed from the gastrointestinal tract). |
| Onset of Action | Oral: 30–90 minutes; IV: immediate (within seconds to minutes) depending on infusion rate. |
| Duration of Action | Oral: sustained effect for 4–6 hours; IV: duration depends on infusion rate and ongoing losses, typically 1–2 hours after infusion stops. |
| Molecular Weight | 74.55 |
10 mEq (1 tablet) orally once daily, titrated to serum potassium levels. Maximum 40 mEq per dose or 100 mEq per day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25%; GFR 10-29 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use or use with extreme caution. |
| Liver impairment | No specific adjustment recommended; monitor potassium levels closely in severe hepatic impairment (Child-Pugh C) due to risk of hyperkalemia. |
| Pediatric use | Neonates: 1-2 mEq/kg/day orally divided every 6-12 hours; Infants and Children: 1-3 mEq/kg/day orally divided every 6-8 hours, not to exceed 1 mEq/kg per dose or 40 mEq per dose. |
| Geriatric use | Start at lower end of dosing range (e.g., 10 mEq once daily); titrate slowly due to age-related decline in renal function and increased risk of hyperkalemia. |
| 1st trimester | Potassium chloride is essential for cellular function and is used to treat or prevent hypokalemia. No teratogenic effects are reported; use is considered safe when indicated. |
| 2nd trimester | Safe for use as indicated. Monitor serum potassium to avoid hyperkalemia, which may cause maternal arrhythmias. |
| 3rd trimester | Safe for use; potassium supplementation may be necessary during labor. Avoid hyperkalemia, which can affect uterine tone and fetal heart rate. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ (POTASSIUM CHLORIDE 10MEQ).
| Placental transfer | Potassium crosses the placenta; fetal serum levels are approximately 90% of maternal levels. No evidence of harm at therapeutic doses. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Supplementation within recommended doses is considered compatible with breastfeeding. Monitor maternal serum potassium to avoid toxicity. |
| Lactation Rating | L1 Safe |
| Teratogenic Risk | No evidence of teratogenicity at therapeutic doses. Potassium chloride is a normal body constituent; excessive maternal hyperkalemia may cause fetal arrhythmias or acidosis. Risk not increased above baseline. |
| Fetal Monitoring | Monitor maternal serum potassium, renal function, and ECG for signs of hyperkalemia. Fetal heart rate monitoring in cases of maternal hyperkalemia. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. High doses causing hyperkalemia may impair reproductive function indirectly. |
■ FDA Black Box Warning
Potassium chloride injections are concentrated and must be diluted before use to avoid fatal hyperkalemia and cardiac arrest. Accidental injection of undiluted potassium concentrate can be fatal.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use of potassium-sparing diuretics (unless monitored)Conditions predisposing to hyperkalemia (e.g., Addison's disease, acute dehydration)
| Precautions | Hyperkalemia risk: monitor serum potassium, ECG, and renal function, Avoid rapid intravenous administration, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Gastrointestinal irritation with oral formulations |
| Food/Dietary | High-potassium foods (bananas, oranges, tomatoes, spinach, potatoes) should be consumed consistently to avoid fluctuations. Avoid salt substitutes containing potassium chloride. Do not consume large amounts of licorice as it may increase potassium loss. |
| Clinical Pearls | Do not administer undiluted as rapid IV push can cause fatal hyperkalemia. Max infusion rate 10 mEq/hour via peripheral line; use central line for rates >10 mEq/hour. Monitor ECG during IV administration. Contraindicated in severe renal impairment, hyperkalemia, or conditions with potassium retention. Consider oral route when possible to reduce risk of phlebitis. |
| Patient Advice | Take with food or after meals to minimize gastrointestinal irritation. · Do not crush or chew extended-release tablets; swallow whole with a full glass of water. · Avoid salt substitutes containing potassium unless directed by your doctor. · Do not abruptly stop taking without medical advice. · Report symptoms of hyperkalemia (muscle weakness, numbness, irregular heartbeat) immediately. |
Loading safety data…